dc.contributor.author | Vasiliadou, I | |
dc.contributor.author | Grose, D | |
dc.contributor.author | Wilson, C | |
dc.contributor.author | Thapa, A | |
dc.contributor.author | Donnelly, O | |
dc.contributor.author | Lee, E | |
dc.contributor.author | Leslie, I | |
dc.contributor.author | Karim, M | |
dc.contributor.author | Hartley, A | |
dc.contributor.author | Partridge, S | |
dc.contributor.author | Medlow, K | |
dc.contributor.author | De Boisanger, J | |
dc.contributor.author | Metcalf, R | |
dc.contributor.author | Williamson, A | |
dc.contributor.author | Haridass, A | |
dc.contributor.author | Noble, D | |
dc.contributor.author | Mactier, K | |
dc.contributor.author | Walter, H | |
dc.contributor.author | Ma, N | |
dc.contributor.author | De Winton, E | |
dc.contributor.author | Cohen, J | |
dc.contributor.author | Rayner, L | |
dc.contributor.author | Geropantas, K | |
dc.contributor.author | Jankowska, P | |
dc.contributor.author | Mason, J | |
dc.contributor.author | Moleron, R | |
dc.contributor.author | Laws, K | |
dc.contributor.author | Ulahannan, D | |
dc.contributor.author | Nallathambi, C | |
dc.contributor.author | Michaelidou, A | |
dc.contributor.author | Nallamilli, S | |
dc.contributor.author | Raouf, S | |
dc.contributor.author | Palmer, K | |
dc.contributor.author | Bienz, M | |
dc.contributor.author | Karet, T | |
dc.contributor.author | Khalique, S | |
dc.contributor.author | Paterson, C | |
dc.contributor.author | Harrington, K | |
dc.contributor.author | Bhide, S | |
dc.contributor.author | Kong, A | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2024-08-02T13:52:14Z | |
dc.date.available | 2024-08-02T13:52:14Z | |
dc.date.issued | 2024-09-01 | |
dc.identifier.citation | International Journal of Cancer, 2024, 155 (5), pp. 883 - 893 | |
dc.identifier.issn | 0020-7136 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6339 | |
dc.identifier.eissn | 1097-0215 | |
dc.identifier.eissn | 1097-0215 | |
dc.identifier.doi | 10.1002/ijc.34963 | |
dc.identifier.doi | 10.1002/ijc.34963 | |
dc.description.abstract | Pembrolizumab has received approval in the UK as first-line monotherapy for recurrent and/or metastatic HNSCC (R/M HNSCC) following the results of the KEYNOTE-048 trial, which demonstrated a longer overall survival (OS) in comparison to the EXTREME chemotherapy regimen in patients with a combined positive score (CPS) ≥1. In this article, we provide retrospective real-world data on the role of pembrolizumab monotherapy as first-line systemic therapy for HNSCC across 18 centers in the UK from March 20, 2020 to May 31, 2021. 211 patients were included, and in the efficacy analysis, the objective response rate (ORR) was 24.7%, the median progression-free survival (PFS) was 4.8 months (95% confidence interval [CI]: 3.6-6.1), and the median OS was 10.8 months (95% CI 9.0-12.5). Pembrolizumab monotherapy was well tolerated, with 18 patients having to stop treatment owing to immune-related adverse events (irAEs). 53 patients proceeded to second-line treatment with a median PFS2 of 10.2 months (95% CI: 8.8-11.5). Moreover, patients with documented irAEs had a statistically significant longer median PFS (11.3 vs. 3.3 months; log-rank p value = <.001) and median OS (18.8 vs. 8.9 months; log-rank p value <.001). The efficacy and safety of pembrolizumab first-line monotherapy for HNSCC has been validated using real-world data. | |
dc.format | Print-Electronic | |
dc.format.extent | 883 - 893 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | WILEY | |
dc.relation.ispartof | International Journal of Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | head and neck squamous cell carcinoma | |
dc.subject | immune‐related adverse events | |
dc.subject | immunotherapy | |
dc.subject | pembrolizumab | |
dc.subject | real‐world data | |
dc.subject | recurrent/metastatic HNSCC | |
dc.subject | systemic treatment | |
dc.subject | Humans | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Male | |
dc.subject | Female | |
dc.subject | Squamous Cell Carcinoma of Head and Neck | |
dc.subject | Middle Aged | |
dc.subject | Aged | |
dc.subject | Retrospective Studies | |
dc.subject | United Kingdom | |
dc.subject | Head and Neck Neoplasms | |
dc.subject | Adult | |
dc.subject | Aged, 80 and over | |
dc.subject | Antineoplastic Agents, Immunological | |
dc.subject | Progression-Free Survival | |
dc.title | The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2024-01-11 | |
dc.date.updated | 2024-08-02T13:51:37Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1002/ijc.34963 | |
rioxxterms.licenseref.startdate | 2024-09-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/38685816 | |
pubs.issue | 5 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | ICR/Students | |
pubs.organisational-group | ICR/Students/PhD and MPhil | |
pubs.organisational-group | ICR/ImmNet | |
pubs.organisational-group | ICR/Students/PhD and MPhil/14/15 Starting Cohort | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1002/ijc.34963 | |
pubs.volume | 155 | |
icr.researchteam | Targeted Therapy | |
icr.researchteam | Functional Genomics | |
dc.contributor.icrauthor | De Boisanger, James | |
dc.contributor.icrauthor | Williamson, Andrew | |
dc.contributor.icrauthor | Harrington, Kevin | |
icr.provenance | Deposited by Mr Arek Surman on 2024-08-02. Deposit type is initial. No. of files: 1. Files: Intl Journal of Cancer - 2024 - Vasiliadou - The use of pembrolizumab monotherapy for the management of head and neck.pdf | |